Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis.

Abstract

OBJECTIVE:

To evaluate the effects of cyclosporine A in the treatment of sebaceous adenitis in dogs.

DESIGN:

Open-label clinical trial.

ANIMALS:

12 dogs with sebaceous adenitis.

PROCEDURE:

Dogs were treated with cyclosporine A at a dosage of 5 mg/kg/d (2.3 mg/lb/d), PO, for 12 months and reevaluated every 4 months. A clinical score was calculated by grading the extent of alopecia and severity of follicular casts as absent, mild, moderate, or severe in each of 17 body regions. Biopsy specimens were obtained and examined histologically and by means of immunohistochemical staining.

RESULTS:

Mean clinical score was significantly decreased, compared with baseline score, after 4 months of treatment and remained low after 8 and 12 months. Histologically, the severity of inflammation was significantly decreased, as were numbers of macrophages, CD3+ T cells, and major histocompatibility complex class II-expressing cells. The percentage of hair follicles with sebaceous glands increased, suggesting regeneration of sebaceous glands. Clinical signs recurred when cyclosporine administration was discontinued.

CONCLUSIONS AND CLINICAL RELEVANCE:

Results suggest that administration of cyclosporine A at a dosage of 5 mg/kg/d may reduce the inflammation associated with sebaceous adenitis in dogs. Long-term treatment appears to be neccessary to control the disease.

• Authors: Monika Linek, Christina Boss, Renate Haemmerling, Marion Hewicker-Trautwein, Lars Mecklenburg
• Journal: Journal of the American Veterinary Medical Association (J Am Vet Med Assoc) Vol. 226 Issue 1 Pg. 59-64 (Jan 01 2005) ISSN: 0003-1488 [Print] United States
• PMID: 15646573 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunosuppressive Agents
• Cyclosporine

Topics

• Administration, Oral
• Animals
• Cyclosporine (therapeutic use)
• Dog Diseases (drug therapy, pathology)
• Dogs
• Female
• Immunosuppressive Agents (therapeutic use)
• Lymphadenitis (drug therapy, pathology, veterinary)
• Male
• Sebaceous Glands
• Severity of Illness Index
• Treatment Outcome